Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of January 2026, specifically reporting transaction notifications dated January 2, 2026. The filing discloses insider trading activities involving the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's Share Save Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of specific equity transactions rather than a financial performance report.
- Instrument: Ordinary shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Transaction Type: Acquisition of shares following the exercise of options granted on November 28, 2022.
- Exercise Price: £11.39 per Ordinary Share.
- Volume: 790 shares per transaction.
- Location: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details two identical transactions executed on the same date by different executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a standard transaction notification required under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Executives Involved: David Redfern (President, Corporate Development) and Victoria Whyte (SVP & Company Secretary).
- Transaction Date: January 2, 2026.
- Total Shares Acquired: 1,580 shares (790 shares each by two executives).
- Plan Details: Shares were acquired via the exercise of options under the Share Save Plan at a fixed price of £11.39.
- Financial Impact: The filing does not disclose the market price at the time of transaction or the total monetary value of the acquisitions.